跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
查看斯高帕斯 (Scopus) 概要
閻 雲
成員
,
臺北醫學大學細胞治療與再生醫學研究中心
https://orcid.org/0000-0003-0815-412X
電子郵件
yyen
tmu.edu
tw
h-index
21361
引文
72
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1994 …
2026
每年研究成果
概覽
指紋
網路
專案
(47)
研究成果
(373)
資料集
(7)
類似的個人檔案
(6)
指紋
查看啟用 Yun Yen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Biochemistry, Genetics and Molecular Biology
Ribonucleotide Reductase
100%
Cancer Cell
69%
Messenger RNA
25%
P53
21%
Carcinogenesis
20%
Gemcitabine
19%
RRM2
18%
DNA Repair
17%
DNA Synthesis
17%
Small Interfering RNA
17%
Autophagy
16%
Programmed Cell Death
15%
RRM2B
15%
Hydroxycarbamide
15%
MicroRNA
14%
Cell Proliferation
14%
High-Mobility Group
14%
Fibroblast Growth Factor Receptor 3
14%
Gene Expression
12%
Promoter Region
12%
Wild Type
11%
Enzyme
11%
Oxidative Stress
11%
Drug Resistance
11%
Genomics
10%
Cytotoxicity
10%
phosphorylation
10%
Prognostic Biomarker
9%
Signal Transduction
9%
DNA Damage
9%
Tumor Progression
9%
Cell Cycle Checkpoint
9%
Cell Growth
9%
Histone Deacetylase
8%
down Regulation
8%
Phosphotransferase
8%
Kinase
8%
Homeostasis
8%
Colon
8%
Ribonucleotide Reductase Inhibitor
8%
Arginine
8%
Tumor Suppressor Protein
8%
Staining
7%
Cell Survival
7%
DNA Damage Response
7%
Drug Therapy
7%
RNA
7%
Enzyme Activity
7%
Vascular Endothelial Growth Factor
7%
Stem Cell
7%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
77%
Ribonucleotide Reductase
44%
Neoplasm
30%
Gemcitabine
27%
Pharmacokinetics
25%
Breast Cancer
22%
Diseases
22%
Solid Malignant Neoplasm
19%
Nanoparticle
19%
Liver Cell Carcinoma
18%
Hydroxycarbamide
18%
Phase I Trials
17%
Camptothecin
16%
Biological Marker
14%
Tumor Growth
13%
Clinical Trial
13%
Chemotherapy Regimens
13%
Messenger RNA
12%
Maximum Tolerated Dose
12%
Carcinogenesis
11%
Colorectal Carcinoma
11%
Small Interfering RNA
11%
3 Aminopicolinaldehyde Thiosemicarbazone
10%
Anticarcinogen
10%
Bile Duct Carcinoma
10%
Carboplatin
9%
Pancreas Cancer
9%
Pharmacodynamics
9%
Drug Resistance
9%
microRNA
8%
Doxorubicin
8%
Bortezomib
8%
Oxaliplatin
8%
Drug Development
8%
Cytotoxicity
8%
Cyclodextrin
7%
Fibroblast Growth Factor Receptor 3
7%
Phase II Trials
7%
Non Small Cell Lung Cancer
6%
Antitumor Activity
6%
Overall Survival
6%
Multiple Myeloma
6%
Docetaxel
6%
Ciclosporin
6%
Capecitabine
6%
Cancer Growth
5%
Histone Deacetylase Inhibitor
5%
Ovary Cancer
5%
Liver Cancer
5%
Progression Free Survival
5%
Medicine and Dentistry
Hepatocellular Carcinoma
19%
Malignant Neoplasm
16%
Breast Cancer
14%
Diseases
14%
Cholangiocarcinoma
13%
Cancer
13%
Chemotherapy
11%
Neoplasm
10%
Overall Survival
10%
Stem Cell
9%
Progression Free Survival
8%
Carcinogenesis
8%
Biological Marker
7%
Tumor
7%
Clinical Trial
7%
High Dose Chemotherapy
7%
Radiation Therapy
6%
Arginine
6%
Hepatobiliary Cancer
6%
Oral Implants
6%
Adenocarcinoma
5%
Drug Megadose
5%
Colorectal Carcinoma
5%
Personalized Medicine
5%
